CRISPR / Cas9 as a healing perspective for Diabetes mellitus type 1

• Autor(a) principal: Silva, Milena Roberta Freire da
• Data de Publicação: 2020
• Outros Autores: Souza, Karolayne Silva, Santos, Milena Danda Vasconcelos, Leite, Kaleen Massari, Silva, Jaqueline dos Santos, Silva, Diego Canuto Bispo da, Fidelis, Kleber Ribeiro, Silva, Rodrigo Reges dos Santos, Santos, Graziele dos, Silva, Renata Pereira Lima da, Nunes, Filipe Silva, Brito, Leandro Paes de, Oliveira, Felicson Leonardo Oliveira, Oliveira, Maria Betânia Melo de
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/10709
• topic: CRISPR/Cas9; Imunologia do DM1; Tratamento.; CRISPR / Cas9; Inmunología de DM1; Tratamiento.; CRISPR / Cas9; Immunology of DM1; Treatment.

Introduction: Diabetes mellitus type 1 (DM1) is considered an autoimmune, chronic, multifactorial disease, which involves the progressive destruction of β cells in pancreatic islets, which are responsible for the production of insulin, thus resulting in the loss of production and secretion of same. It is estimated that more than 30 thousand Brazilians suffer from this pathology. Three mechanisms are responsible for the destruction of these cells: genetic susceptibility, autoimmunity and environmental factors. In this sense, the objective of this study was to carry out a survey about the main perspectives of cure of this disease using the CRISPR / Cas9 system. Methodology: This is a bibliographic review with searches in national and international electronic databases in Portuguese and English. Results: Since this pathology still has no cure, only treatment, the CRISPR / Cas9 system emerges as a promising therapy, as well as therapy with pluripotent menenchymal stem cells (MSC), which have the functionality, mainly, of repair and survival of β cells from pancreatic islets, MSCs have the ability to modify the microenvironment of the areas of pancreatic injury, canceling the autoimmune destruction against β cells and can restore the patient's normoglycemia. Conclusion: Bearing in mind that this is a pathology of a genetic nature, CRISPR / Cas9 associated with therapy with pluripotent mensenchymal cells has been shown to be a versatile and effective tool in the treatment of DM1. However, there is a need for further research capable of inducing strategies for the improvement of genetic alterations and greater efficiency of the therapeutic effect.